Nesiritide

Summary

Nesiritide (Natrecor) is a recombinant form of human BNP approved for the intravenous treatment of acutely decompensated congestive heart failure with dyspnea at rest or minimal activity. It produces balanced arterial and venous vasodilation and promotes diuresis and natriuresis.

Mechanism of Action

Recombinant human B-type natriuretic peptide (BNP) that binds to guanylate cyclase-coupled natriuretic peptide receptors (NPR-A and NPR-B), increasing intracellular cGMP, leading to smooth muscle relaxation, vasodilation, natriuresis, and diuresis. Reduces preload and afterload in decompensated heart failure.

Routes of Administration

Goals & Uses

• Reduction of preload and afterloadHemodynamicHigh
• Natriuresis and diuresisFluid/electrolyte ManagementModerate
• Relief of dyspnea in acutely decompensated heart failureCardiovascularHigh
• Reduction of BNP/neurohormonal activationNeurohormonalModerate

Contraindications

• Hypersensitivity to nesiritide or any componentAllergyHigh
• Systolic blood pressure < 90 mmHgHemodynamicHigh
• Cardiogenic shockCardiovascularHigh
• Low cardiac filling pressureHemodynamicHigh

Adverse Effects

• HeadacheNeurologicCommonPain in the head or upper neck
• HypotensionCardiovascularCommonLow blood pressure
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Back painMusculoskeletalUncommonPain in the back
• BradycardiaCardiovascularRare
• Worsening renal functionRenalUncommon

Drug Interactions

• Antihypertensives (e.g., ACE inhibitors, ARBs, calcium channel blockers)Moderate
• Vasodilators (e.g., nitrates, hydralazine)Moderate
• DiureticsModerateMay worsen dehydration or electrolyte imbalance

Population Constraints

• Pregnancy (Category C)ReproductiveRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Elderly patientsAgeRelative

Regulatory Status

• European UnionUnknownNot widely approved or marketed in EU; regulatory status unclear
• United StatesApprovedApproved: Acutely decompensated congestive heart failure in patients with dyspnea at rest or with minimal activityFDA approved August 2001 (NDA 021-49); marketed as Natrecor by Scios/Johnson & Johnson; use has declined substantially
• United KingdomUnknownNot MHRA-approved as a standard product; limited availability

FDA-approved in 2001 for acutely decompensated heart failure. Use declined significantly following studies raising concerns about renal function and mortality; the ASCEND-HF trial (2011) showed no mortality benefit. Still approved but rarely used due to availability of alternatives and safety concerns.

Evidence & Sources

No sources recorded yet.